Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma
Michael A. Gorin, Hiten D. Patel, Steven P. Rowe, Noah M. Hahn, Hans J. Hammers, Alice Pons, Bruce J. Trock, Phillip M. Pierorazio, Thomas R. Nirschl, Daniela C. Salles, Julie E. Stein, Tamara L. Lotan, Janis M. Taube, Charles G. Drake, Mohamad E. Allaf
Topics & Concepts
MedicineNivolumabTolerabilityRenal cell carcinomaInternal medicineRashAdverse effectOncologyUrologySurgeryGastroenterologyCancerImmunotherapyRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments